Ethanesulfonic acid (4-nitro-2-phenoxy-phenyl)-amide | 51765-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethanesulfonic acid (4-nitro-2-phenoxy-phenyl)-amide
• 英文别名: N-(4-nitro-2-phenoxyphenyl)ethanesulfonamide
• CAS: 51765-74-3
• 化学式: C₁₄H₁₄N₂O₅S
• 分子量: 322.342
• InChiKey: XIMJCIQTECXXJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND SEX STEROIDS AS A COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF DISMENORRHEA
  申请人：Pharmacia Corporation

  公开号：EP1363669A2

  公开（公告）日：2003-11-26
• COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHENIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY
  申请人：Pharmacia Corporation

  公开号：EP1670417A2

  公开（公告）日：2006-06-21
• US7432261B2
  申请人：——

  公开号：US7432261B2

  公开（公告）日：2008-10-07
• [EN] METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND SEX STEROIDS AS A COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF DISMENORRHEA<br/>[FR] METHODE D'UTILISATION D'UN INHIBITEUR DE LA CYCLOOXYGENASE-2 ET DE STEROIDES SEXUELS DANS UNE POLYTHERAPIE POUR TRAITER ET PREVENIR LA DYSMENORRHEE
  申请人：PHARMACIA CORP

  公开号：WO2002062391A2

  公开（公告）日：2002-08-15

  The present invention provides methods for the treatment and prevention of dysmenorrhea in a woman using a combination of a cyclooxygenase-2 inhibitor and sex steroids.
• [EN] COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHENIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY<br/>[FR] COMPOSITIONS A BASE D'INHIBITEUR SELECTIF DE LA CYCLOOXYGENASE-2 ADMINISTREES DANS DES CONDITIONS D'HYPOTHERMIE POUR LE TRAITEMENT DE LESIONS OU DE TROUBLES DU SYSTEME NERVEUX CENTRAL INDUITS PAR UNE ISCHEMIE
  申请人：PHARMACIA CORP

  公开号：WO2005037193A2

  公开（公告）日：2005-04-28

  Methods and compositions for the treatment of reduced blood flow to the central nervous system are provided. The method comprises administering to a subject a composition having a cyclooxygenase-2 selective inhibitor in combination with applying hypothermic conditions to the subject to provide improved neurological function in subjects with ischemic mediated central nervous system damage including stroke, traumatic brain and spinal cord injury.